Bringing the Oncology Community Together

First Generic Version of Capecitabine Gains FDA Approval

Silas Inman
Published Online: Monday, September 16, 2013
Dr Kathleen Uhl

Kathleen Uhl, MD

The FDA has approved the first generic formulation of capecitabine (Xeloda), an oral chemotherapeutic that is currently approved to treat patients with metastatic colorectal cancer (mCRC) and metastatic breast cancer (MBC).

Genentech manufactures capecitabine, which became the first approved oral chemotherapy in 1998. The generic version of capecitabine will be marketed by Teva Pharmaceuticals USA at 150 and 500 milligram doses. According to the FDA, on average, the cost of a generic drug is 80% to 85% lower than the brand name equivalent, amounting to billions of dollars saved on prescription drugs each year.

The patent for capecitabine is set to expire on December 14, 2013. The global sales for the agent have continued to rise since its approval. It is considered a “blockbuster” drug, a distinction reserved for treatments that generate more than $1 billion in annual revenue. To date, a generic version of the drug has not been made available.

“Generic drugs are important options that allow greater access to healthcare for all Americans,” said Kathleen Uhl, MD, the acting director of the Office of Generic Drugs in the FDA’s Center for Drug Evaluation and Research. “This medication is widely used by people living with cancer, so it is important to have access to affordable treatment options.”

Since its initial approval in MBC, capecitabine has become widely utilized in several settings. The drug is most well known for its use in combination strategies, specifically in HER2-positive MBC, where it is commonly administered along with lapatinib (Tykerb). As a single-agent, capecitabine has demonstrated efficacy as a first-line therapy for patients with mCRC, following complete resection of the primary tumor when fluoropyrimidine therapy is preferred, and as a treatment for patients with HER2-negative MBC following prior treatment with anthracyclines and taxanes.

Even though the drug has been widely available for more than a decade, investigators are continuing to assess the drug’s efficacy in multiple ongoing clinical trials. As of today’s approval, the chemotherapy is being examined in combination or as a single-agent in over 300 open studies across a variety of diseases. Although the drug is not specifically FDA approved for other indications outside of breast cancer and colorectal cancer, capecitabine is widely used as a treatment for patients with gastric cancer in the first-line setting and in combination with oxaliplatin for patients with stage II to IIIb disease.

The standard schedule for capecitabine is 8 cycles of 1250 mg/m2 administered orally twice daily for 2 weeks followed by 1 week of rest. The most common adverse reactions with capecitabine are diarrhea, hand-and-foot syndrome, nausea, and vomiting. Additionally, the medication has a boxed warning regarding an adverse capecitabine and anticoagulant interaction.

Related Articles
Experts Debate Utility of Genomic Profiling in Daily Practice
Although the potential for next-generation sequencing of breast cancer tumors to improve treatment strategies is widely recognized, questions swirl about the optimal use of such increasingly available technologies in clinical practice for today’s patients.
AR Findings Highlight Detailed Tumor-Profiling Study
A wide-ranging analysis of more than 5500 breast cancer tumors that combined genomic and protein expression testing has identified promising targets to explore for treating patients with poor prognoses, with particularly notable findings involving androgen receptor (AR) expression
First- and Later-line Use of Panitumumab in mCRC
Panelists describe the results of clinical trials of the EGFR inhibitor panitumumab as first-line or later-line therapy for patients with metastatic colorectal cancer and the importance of RAS testing for patient selection.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
OncLive Resources

OncLive TV
Oncology Nurses
Web Exclusives

About Us
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.